SeekIn Inc, has obtained a license from Bio-Rad Laboratories, Inc., to develop and market oncology precision medicine molecular diagnostic test kits utilizing Bio-Rad’s Droplet Digital® PCR (ddPCR®) technology.
SeekIn will leverage Bio-Rad's ddPCR® technology to developthe molecular diagnostics test kits, which will run on Bio-Rad’s ddPCR® platforms.
Dr. Mao Mao, the founder and CEO of SeekIn said that over the past several years they have finished the development and validation of several product prototypes on Bio-Rad's QX200TM Droplet Digital® PCR System,which is considered the most sensitive instrument to detect and enable absolute quantification of cancer mutations. Through this collaboration, these cutting-edge cancer molecular diagnostics will provide clinicians and patients in China with systematic and comprehensive cancer precision medical solutions in multiple clinical settings, such as companion diagnostics, recurrence monitoring, minimal residual disease, prognosis stratification, and treatment response evaluation.